Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal

By Ludwig Burger and Dina Kartit March 13 (Reuters) — France’s Sanofi SA on Monday agreed to acquire Provention Bio Inc for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies,…

Read More